retatrutide 3 receptors First phase data, a Triumph of Science! Retatrutide | GLP-1R/GIPR/GCGR ligand |

10.1038/s41467-024-54080-w 105 VarnumA

Second Nature Second Nature charges an all-inclusive monthly fee covering medication, delivery, dietitian coaching, app access, and peer support: Wegovy programme: ~99-249 per month depending on dose Mounjaro programme: pricing available on the Second Nature website Non-medication programme: from 33/month WeightWatchers WeightWatchers UK GLP-1 programme is a membership fee for the behavioural support only

Additional risk factors commonly present in patients prescribed GLP-1 receptor agonists include: Reduced physical activity and prolonged immobility Hypertension and other cardiovascular comorbidities Dyslipidaemia contributing to atherosclerosis Advanced age , as thrombotic risk increases with ageing Other important VTE risk factors include: Previous VTE or family history of clotting disorders Thrombophilia (inherited or acquired clotting disorders) Active cancer or cancer treatment Oestrogen-containing medications (HRT, combined oral contraceptives) Pregnancy and postpartum period Recent surgery, trauma or hospitalisation Long-haul travel with prolonged immobility Smoking When patients taking GLP-1 receptor agonists experience thrombotic events, it is important to consider these pre-existing risk factors as they often contribute significantly to clotting risk in this population

No head-to-head retatrutide vs tirzepatide or retatrutide vs semaglutide trial has been conducted

Holz Iv GG, Kiihtreiber WM, Habener JF